Why the study?
Does the molecular weight of LMWHs affect their dependence on renal clearance and potential for accumulation in patients with renal impairment?
Does the molecular weight of LMWHs affect their dependence on renal clearance and potential for accumulation in patients with renal impairment?
LMWHs with higher molecular weights, such as tinzaparin, undergo more extensive non-renal clearance, making them potentially safer options for patients with renal insufficiency due to a lower risk of accumulation.
Answers are grounded in this paper and cite their sources.
May guide LMWH selection in renal impairment; leaves open prospective outcome trials.
Since low-molecular-weight heparins (LMWHs) are eliminated preferentially via the kidneys, the potential for accumulation of these agents (and an increased risk of bleeding) is of particular concern in populations with a high prevalence of renal impairment, such as the elderly and patients with cancer. The risk of clinically relevant accumulation of anticoagulant activity as a result of a reduction in renal elimination appears to differ between LMWHs. This review describes the elimination pathways for LMWHs and assesses whether the relative balance between renal and non-renal (cellular) clearance may provide a mechanistic explanation for the differences in accumulation that have been observed between LMWHs in patients with impaired renal function. Clearance studies in animals, cellular binding studies and clinical studies all indicate that the balance between renal and non-renal clearance is dependent on the molecular weight (MW): the higher the MW of the LMWH, the more the balance is shifted towards non-renal clearance. Animal studies have also provided insights into the balance between renal and non-renal clearance by examining the effect of selective blocking of one of the elimination pathways, and it is most likely that cellular clearance is increased to compensate for decreased renal function. Tinzaparin (6,500 Da) has the highest average MW of the marketed LMWHs, and there is both clinical and preclinical evidence for significant non-renal elimination of tinzaparin, making it less likely that tinzaparin accumulates in patients with renal impairment compared with LMWHs with a lower MW distribution. On the basis of our findings, LMWHs that are less dependent on renal clearance may be preferred in patient populations with a high prevalence of renal insufficiency.
No takes yet. Share an insight, caveat, or question.
JOHANSEN et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: